All In Biotech

Drug Trial Radar · NCT02286921

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

222

Actual

Start

Jan 2015

Primary completion

Oct 26, 2018

Study completion Feb 21, 2020

Sponsor

Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense
First posted
Nov 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC) post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open label study to determine if treatment with intramuscular T given on a dose/schedule designed to result in rapid cycling from the polar extremes of supraphysiologic to near castrate levels \[i.e. Bipolar Androgen Therapy (BAT)\] will improve primary and secondary objectives vs. enzalutamide as standard therapy.

Conditions

  • Castration Resistant Metastatic Prostate Cancer

Interventions

  • Testosterone cypionateDrug

    Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.

  • EnzalutamideDrug

    Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.

  • Testosterone EnanthateDrug

    Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic ProgressionTime frame: up to 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Unversity of Alabama

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • Piedmont Cancer Institute

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Tulane University Medical Center

    New Orleans, Louisiana

  • University of Maryland

    Baltimore, Maryland

  • SKCCC at Johns Hopkins

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Neraska Cancer Specialists

    Omaha, Nebraska

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Cleveland Clinic

    Cleveland, Ohio

  • Allegheny Health Network

    Pittsburgh, Pennsylvania

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Washing

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.